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Summary Six hundred and eighty-four primary breast cancers from the International (Ludwig) Breast Cancer
Study Group (IBCSG) were studied for Helix pomatia lectin (HPA) binding. There was a weak correlation
between lymph node-positive and HPA positive (P = 0.04). In our series there was a large advantage in
disease-free survival (DFS) and overall survival (OS) for node-negative patients (P<0.0001 DFS and OS).
However, there was no such advantage for HPA-negative patients (P = 0.23 DFS and P = 0.32 OS). We
conclude that in this randomised patient group HPA is of no clinical predictive value.
Reports on the prognostic importance of Helix pomatia lectin
binding in human breast cancer have been conflicting. In
1983 Leathem published that 14/14 normal breast specimens
and 24/26 breast cancers stained positively with Helix
pomatia lectin (Leathem et al., 1983). This was followed by
two meetings abstracts (Leathem et al., 1984; Leathem et al.,
1985) from the same group that demonstrated a strong rela-
tionship between HPA binding and axillary lymph node
metastases. In 1987 Fenlon et al., in a series of 100 tumours,
reported a significant correlation between HPA binding,
tumour stage, local recurrence and survival (Fenlon et al.,
1987). The authors did not comment on menopausal status.
In 1987 Leathem and Brooks reported that HPA positivity
correlated with the time to first recurrence and with survival,
but that this was only true for premenopausal women
(Leathem & Brooks, 1987). This is in contrast to the results
of Fukutomi et al. (1989) who found HPA positivity to be
strongly correlated with poor survival, irrespective of
menopausal status (Fukutomi et al., 1989). In a recent report
of 153 breast carcinomas using the same biotinylated lectin
the significance had dropped to P = 0.05 (Fukutomi et al.,
1991). All of these earlier studies were carried out on small
numbers ofpatients and there was a need for a careful analysis
of large numbers of cases in different centres. Last year,
Brooks and Leathem published a larger series of 373 cases
(Brooks & Leathem, 1991). They found a strong correlation
between HPA positivity and the presence of lymph node
metastases. In this study there is no comment on whether this
correlates with menopausal status and whether this is a com-
pletely new data set or an extension of their 179 cases
previously reported (Leathem & Brooks, 1987). The study of
Galea et al. (1991) on 459 cases could not confirm these data
or their original observation (Fenlon et al., 1987). On the
basis of these conflicting results we carried out a pilot study
on 363 cases randomised from the IBCSG (Ludwig) Trial V
database. We found no correlation between HPA positivity
and survival (Taylor et al., 1991). In view of these findings
we have enlarged the study to 684 cases from this same data
set to re-analyse our HPA positivity in relation to all
recorded clinical and pathological parameters. We report
here a summary of our findings and some of the conflicting
views in this area.
Materials and methods
Cases were taken at random from 13 of the participating
centres in the IBCSG Trial V. Details of this trial have been
reported elsewhere (Ludwig Breast Cancer Study Group,
1988; Ludwig Breast Cancer Study Group, 1989). We have
studied the association between HPA positivity and other
prognostic factors and the effect of HPA binding on out-
come. In view of the differences in the literature with staining
techniques a pilot study was carried out by both the direct
peroxidase conjugated method used by Galea (Galea et al.,
1991) and the indirect avidin-biotin techniques described by
Fukutomi (Fukutomi et al., 1989, 1991). Similar staining
results were obtained for each and the positivity was
inhibited by the appropriate sugar (N-acetyl-galactosamine),
indicating that both methods produced specific staining.
Figures 1 and 2 show similar fields of the same tumours
stained by both methods. Both the tumour and the vascular
endothelium show similar patterns of reactivity. Owing to the
simplicity of the method all subsequent cases were stained
using the direct method. All cases were scored according to
the method described by Brooks & Leathem (1991), with all
positive cases having either greater than 5% of the cells
strongly positive to greater than 50% of the cells weakly
positive. Samples were coded according to the patient ran-
domisation number and all slides were reviewed independ-
ently by two pathologists (RA and BAG). In 10% of cases
difficulty was encountered in using the scoring scheme and
for these a consensus view was taken. All results were sent to
the Biostatistics Center, Dana Farber Cancer Institute, where
clinical correlations were studied.
Results
It was noted that in a large proportion of cases there was
staining of normal breast vascular endothelium and
associated erythrocytes. On a representative sample of ran-
domly selected cases (Table I) there was no clear correlation
between positivity of tumour and normal tissues. Table IIA
shows that there is a very weak correlation between Helix
pomatia positivity and lymph node status and no correlation
between HPA binding and either DFS or OS (Table IIB). In
a detailed analysis of HPA binding and other patient charac-
teristics no correlations were found with menopausal status,
ER, PR, tumour grade, vessel invasion, histological type
pathological tumour size or treatment groups (Tables III and
IV). In addition, HPA does not predict a poorer prognosis in
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Figure I a, Photomicrograph of a breast carcinoma stained with the direct method for HPA immunoreactivity. (x 360). Note
staining on vascular endothelium (arrows). b, The same tumour stained by the indirect method. Note the similar staining pattern of
the tumour and the blood vessels. (x 360). Note staining on vascular endothelium (arrows).
Table I Helix pomatia lectin staining
Tumour 68+ 32-
Blood 33+ 35- 13+ 19-
vessels
Normal 18 ± 15- 9 ± 26- 4 ± 9- 3 ± 16-
breast
+ Positive staining. - Negative staining. ± Positive and negative
staining in different areas.
Table IIA Helix pomatia lectin binding by nodal status
Number Number Percent P-value
negative positive positive (chi-square)
Node negative 106 212 67% 0.04
Node positive 96 270 74% (-vs. + )
1-3 Nodes 61 147 71%
4 + Nodes 35 123 78%
Table IIB Six-year disease-free survival (DFS) and overall survival (OS)
status and Helix pomatia lectin positivity
according to nodal
6-Year 6-Year P-value
Pts Relapsed DFS ± e. P-value Deaths OS ± e
Node negative 318 105 66±3 <0.0001 55 83±2 <0.00
Node positive 366 197 47±3 131 62±3 01
HPA- 202 83 59±4 0.23 50 76± 3 0.32
HPA+ 482 219 55±2 136 70±2
any of the above sub-groups for DFS or OS. In the lymph
node positive group there was a correlation of HPA with
increased tumour grade, but there were only 32 cases in the
Grade 1 category, making this result of doubtful significance.
Discussion
This detailed analysis has failed to confirm some of the
previous published data. As we have a similar percentage of
positive cases and have demonstrated specificity of staining,
it is difficult to explain away the differences method-
ologically. As Brooks and Leathem have recently stated that
the differences seen in previously published data can be
explained on the basis of staining techniques (Brooks &
Leathem, 1991), a number of points need to be addressed
here. Firstly, Brooks and Leathem state that they use an
indirect method because this piovides a clinical correlation
not seen with direct HPA-peroxidase conjugate technique.
We found no difference in staining pattern between the
avidin-biotin and the direct method in our pilot study. It can
not be excluded that using other sources of HPA and stain-
ing methods a correlation with survival would be observed,
but it can be concluded that HPA binding as demonstrated
b
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Table III Correlations between Helix pomatia (HPA) positivity and other patient
characteristics
N-patients
HPA
Number Number Percent P-value
negative positive positive (chi-square)
Total 106 212 67%
Menopausal status
Premenopausal
Postmenopausal
ER status
ER-: 0-9fmol
ER+: > 10 fmol
Unknown
PR status
PR-: 0-9fmol
PR+: 10fmol
Unknown
Tumour grade
1
2
3
Unknown
Vessel invasion
Negative
Positive
Unknown
Age-premenopausal
<40
40-49
) 50
62 115 65%
44 97 69%
42
54
10
51
37
18
13
38
45
10
52
49
5
14
31
17
76
114
22
95
78
39
29
99
69
15
103
99
10
22
70
23
64%
68%
69%
65%
68%
68%
69%
72%
61%
60%
66%
67%
67%
61%
69%
58%
Age-postmenopausal
<60
> 60
Histology
Non-invasive
Limited invasion
Intraductal w/stomal inv
Inv ductal
Inv lobular
Special features
Inv ductal and lobular
Pathologic T-size
< 2.0 cm
>2.0 cm
25 47 65%
19 50 72%
S 5
4
78
9
5
0
2
14
4
147
21
9
6
67%
74%
50%
65%
70%
64%
100%
49 100 67%
55 103 65%
133 64%
79 72%
aP-value calculations do not include
here with the appropriate sugar controls does not. The
avidin-biotin-peroxidase method was used by Fukutomi et al.
(1989) in the paper quoted by Brooks in support of their own
findings. In the flow cytometry paper of Alam et al. (1990),
that also found a positive correlation between HPA positivity
and lymph node involvement, the authors used a direct tech-
nique. They, however, state that they selected a cut off when
related to grade and lymph node involvement of 20% of cells
positive as this was the most informative (Alam et al., 1990).
It is difficult therefore to draw any conclusions from this
publication until it is repeated by other groups with a larger
data set.
We do not rule out the possibility that two staining
methods with a lectin may give a different result dependent
upon the cut off used for positivity. The difficulty is that with
any study there is a statistical chance finding of a significant
correlation between any given parameter and any selected cut
'unknown' categories.
off point. We must conclude that there is no consistent data
to strongly support the view that the localisation of HPA
epitopes is of clinical significance. This issue will not be
resolved on the basis of staining procedures. As discussed by
Brooks and Leathem (1991), the binding of lectins is very
complex and poorly understood. It is therefore essential that
the reactive epitopes are properly characterised and more
suitable antibodies with defined specificity made available.
We await with interest the biochemical evidence for, and
characterisation of, the glycoconjugate that Leathem et al.,
first identified immunocytochemically in 1983.
The lack of correlation between staining of tumour and
normal tissues is very important because, although addressed
in part by correspondence in the Lancet between Leathem
(Leathem & Brooks, 1987) and Grundbacher (Grundbacher
et al., 1987), the possible confounding effects of any analyses
by secretor status and the binding ability of Helix pomatia
0.47
0.54a
0.64a
0.14a
0.94a
0.36
0.36
Treatment
PeCT
No PeCT
0.72
75
31
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Table IV Correlations between Helix pomatia positivity and other patient
characteristics
N+patients
HPA
Number Number Percent P-value
negative positive positive (chi-square)
Total 96 270 74%
Menopausal status
Premenopausal
Postmenopausal
Nodal status
1-3 N+
>4 N+
ER status
ER-: 0-9fmol
ER+: )l0fmol
Unknown
PR status
PR-: 0-9 fmol
PR+:) lOfmol
Unknown
Tumour grade
I
2
3
Unknown
58
38
183 76%
87 70%
61 147 71%
35 123 78%
33
56
7
36
42
18
15
36
39
6
89
150
31
114
114
42
17
128
116
9
73%
73%
82%
76%
73%
70%
53%
78%
75%
Vessel invasion
Negative
Positive
Age-premenopausal
<40
40-49
.> 50
Age-postmenopausal
<60
Pathologic T-size
< 2.0cm
>2.0cm
Histology
Non-invasive
Limited invasion
Intraduct w/stromed inv
Inv ductal
Inv lobular
Special features
Inv ductal and lobular
Treatment
Long duration
Short duration
23
67
15
30
13
22
16
38
56
0
3
0
80
5
2
0
52 69%
210 76%
47
98
38
56
31
87
178
0
12
I
227
12
1
9
76%
77%
75%
72%
66%
70%
76%
0%
80%
100%
74%
71%
33%
100%
63 167 73%
33 103 76%
for Blood group A and AB should not be ignored. It could
be argued that in order to analyse these data properly it is
necessary to work with material from patients of blood
groups B and 0 and to know in all cases the secretor status.
Using the indirect technique Fukutomi et al. (1991) found
that red cells in patients of blood group A were positively
stained. Our incidence of 46% positive staining on the
endothelium would correlate with binding to blood group A
and AB determinants and the positivity on the luminal sur-
face of the normal mammary glandular elements could in
part reflect secretor status. Thus positivity of the tumours
could be due to a number of factors. Until the HPA-binding
ligands in the tumours are biochemically defined and demon-
strated to be different from the determinants on the normal
epithelium, there is no reason to assume that the 40% of
cases that stain positively in both the tumour and the adja-
cent normal tissue carry different epitopes in these two sites.
Until that is proven, any hypotheses concerning the gaining
of HPA binding sites in the progression to metastasis is
premature.
As stated recently by Baum (Baum, 1991), even if it were
possible to demonstrate a group of patients at higher risk of
lymph node involvement, the false negative and false positive
rates of these methods is such that this would not be a
significant advance in the management of breast cancer.
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